Zydus Lifesciences Management
Management criteria checks 3/4
Zydus Lifesciences' CEO is Sharvil Patel, appointed in Apr 2017, has a tenure of 7.58 years. total yearly compensation is ₹300.00M, comprised of 60% salary and 40% bonuses, including company stock and options. directly owns 0.001% of the company’s shares, worth ₹14.40M. The average tenure of the management team and the board of directors is 6.5 years and 7.3 years respectively.
Key information
Sharvil Patel
Chief executive officer
₹300.0m
Total compensation
| CEO salary percentage | 60.0% |
| CEO tenure | 7.6yrs |
| CEO ownership | 0.001% |
| Management average tenure | 6.5yrs |
| Board average tenure | 7.3yrs |
Recent management updates
Recent updates
Here's Why We Think Zydus Lifesciences (NSE:ZYDUSLIFE) Is Well Worth Watching
Sep 14
Zydus Lifesciences Limited's (NSE:ZYDUSLIFE) Business And Shares Still Trailing The Market
Aug 30Zydus Lifesciences Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
Aug 14Zydus Lifesciences Limited's (NSE:ZYDUSLIFE) CEO Compensation Is Looking A Bit Stretched At The Moment
Aug 03Zydus Lifesciences (NSE:ZYDUSLIFE) Will Pay A Smaller Dividend Than Last Year
Jul 19Zydus Lifesciences' (NSE:ZYDUSLIFE) Shareholders Will Receive A Smaller Dividend Than Last Year
Jul 05Zydus Lifesciences (NSE:ZYDUSLIFE) Will Pay A Smaller Dividend Than Last Year
Jun 20Zydus Lifesciences (NSE:ZYDUSLIFE) Could Easily Take On More Debt
Jun 10Zydus Lifesciences (NSE:ZYDUSLIFE) Will Pay A Smaller Dividend Than Last Year
May 25Does Zydus Lifesciences (NSE:ZYDUSLIFE) Deserve A Spot On Your Watchlist?
Mar 18Earnings Not Telling The Story For Zydus Lifesciences Limited (NSE:ZYDUSLIFE) After Shares Rise 28%
Feb 28Analyst Estimates: Here's What Brokers Think Of Zydus Lifesciences Limited (NSE:ZYDUSLIFE) After Its Third-Quarter Report
Feb 12Zydus Lifesciences (NSE:ZYDUSLIFE) Could Easily Take On More Debt
Dec 27Here's Why Zydus Lifesciences (NSE:ZYDUSLIFE) Has Caught The Eye Of Investors
Dec 06With EPS Growth And More, Zydus Lifesciences (NSE:ZYDUSLIFE) Makes An Interesting Case
Aug 23Zydus Lifesciences' (NSE:ZYDUSLIFE) Dividend Will Be Increased To ₹6.00
Jul 17We Think Zydus Lifesciences (NSE:ZYDUSLIFE) Can Stay On Top Of Its Debt
Jul 15Zydus Lifesciences' (NSE:ZYDUSLIFE) Upcoming Dividend Will Be Larger Than Last Year's
Jun 24Zydus Lifesciences (NSE:ZYDUSLIFE) Is Increasing Its Dividend To ₹6.00
Jun 10Zydus Lifesciences' (NSE:ZYDUSLIFE) Dividend Will Be Increased To ₹6.00
May 21Zydus Lifesciences (NSE:ZYDUSLIFE) Seems To Use Debt Quite Sensibly
Feb 15We Think Zydus Lifesciences (NSE:ZYDUSLIFE) Can Stay On Top Of Its Debt
Nov 13CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | ₹42b |
| Mar 31 2024 | ₹300m | ₹180m | ₹38b |
| Dec 31 2023 | n/a | n/a | ₹30b |
| Sep 30 2023 | n/a | n/a | ₹28b |
| Jun 30 2023 | n/a | n/a | ₹25b |
| Mar 31 2023 | ₹263m | ₹180m | ₹20b |
| Dec 31 2022 | n/a | n/a | ₹21b |
| Sep 30 2022 | n/a | n/a | ₹20b |
| Jun 30 2022 | n/a | n/a | ₹22b |
| Mar 31 2022 | ₹200m | ₹180m | ₹22b |
| Dec 31 2021 | n/a | n/a | ₹23b |
| Sep 30 2021 | n/a | n/a | ₹23b |
| Jun 30 2021 | n/a | n/a | ₹23b |
| Mar 31 2021 | ₹263m | ₹180m | ₹22b |
| Dec 31 2020 | n/a | n/a | ₹18b |
| Sep 30 2020 | n/a | n/a | ₹17b |
| Jun 30 2020 | n/a | n/a | ₹13b |
| Mar 31 2020 | ₹250m | ₹247m | ₹12b |
| Dec 31 2019 | n/a | n/a | ₹12b |
| Sep 30 2019 | n/a | n/a | ₹14b |
| Jun 30 2019 | n/a | n/a | ₹17b |
| Mar 31 2019 | ₹250m | ₹248m | ₹18b |
| Dec 31 2018 | n/a | n/a | ₹20b |
| Sep 30 2018 | n/a | n/a | ₹20b |
| Jun 30 2018 | n/a | n/a | ₹21b |
| Mar 31 2018 | ₹250m | ₹248m | ₹18b |
Compensation vs Market: Sharvil's total compensation ($USD3.56M) is above average for companies of similar size in the Indian market ($USD1.09M).
Compensation vs Earnings: Sharvil's compensation has been consistent with company performance over the past year.
CEO
Sharvil Patel (45 yo)
7.6yrs
Tenure
₹300,000,000
Compensation
Dr. Sharvil Pankajbhai Patel has been Managing Director of Zydus Lifesciences Limited (formerly known as Cadila Healthcare Limited) since April 1, 2017 and previously served as its Joint Managing Director...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| MD & Executive Director | 7.6yrs | ₹300.00m | 0.0015% ₹ 14.4m | |
| COO & Executive Director | 7.3yrs | ₹140.00m | 0.035% ₹ 338.8m | |
| President & CEO of America | 1.1yrs | no data | no data | |
| Chief Financial Officer | no data | ₹54.31m | no data | |
| Head of Investor Relations | no data | no data | no data | |
| Company Secretary & Compliance Officer | 5.8yrs | ₹2.09m | no data |
6.5yrs
Average Tenure
Experienced Management: ZYDUSLIFE's management team is seasoned and experienced (6.5 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| MD & Executive Director | 27.3yrs | ₹300.00m | 0.0015% ₹ 14.4m | |
| COO & Executive Director | 7.3yrs | ₹140.00m | 0.035% ₹ 338.8m | |
| Non-Executive Chairman | 29.5yrs | ₹1.20m | 74.98% ₹ 734.3b | |
| Independent Director | 8.5yrs | ₹4.00m | no data | |
| Non-Executive Non-Independent Director | 27.3yrs | ₹4.00m | 0.0012% ₹ 11.4m | |
| Independent Non-Executive Director | 5.9yrs | ₹4.10m | no data | |
| Independent Director | 2yrs | ₹3.50m | no data | |
| Independent Director | 2yrs | ₹3.50m | no data | |
| Independent Director | less than a year | no data | 0.00044% ₹ 4.3m |
7.3yrs
Average Tenure
56yo
Average Age
Experienced Board: ZYDUSLIFE's board of directors are considered experienced (7.3 years average tenure).